布比卡因脂质体髂筋膜阻滞预防性镇痛对老年髋部骨折围术期认知功能影响的临床研究

注册号:

Registration number:

ChiCTR2400081787 

最近更新日期:

Date of Last Refreshed on:

2024-03-12 09:57:00 

注册时间:

Date of Registration:

2024-03-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

布比卡因脂质体髂筋膜阻滞预防性镇痛对老年髋部骨折围术期认知功能影响的临床研究

Public title:

Clinical study on the effect of bupivacaine liposome iliac fascia block prophylactic analgesia on perioperative cognitive function in elderly patients with hip fractures

注册题目简写:

English Acronym:

研究课题的正式科学名称:

布比卡因脂质体髂筋膜阻滞预防性镇痛对老年髋部骨折围术期认知功能影响的临床研究

Scientific title:

Clinical study on the effect of bupivacaine liposome iliac fascia block prophylactic analgesia on perioperative cognitive function in elderly patients with hip fractures

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李静如 

研究负责人:

蒋鹏 

Applicant:

Li Jingru 

Study leader:

Jiang Peng 

申请注册联系人电话:

Applicant telephone:

+86 156 6516 2330

研究负责人电话:

Study leader's
telephone:

+86 139 1455 6527

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

903210684@qq.com

研究负责人电子邮件:

Study leader's E-mail:

doctorjp@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省镇江市京口区解放路438号

研究负责人通讯地址:

江苏省镇江市京口区解放路438号

Applicant address:

438 Jiefang Road, Jingkou District, Zhenjiang City, Jiangsu Province

Study leader's address:

438 Jiefang Road, Jingkou District, Zhenjiang City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏大学附属医院

Applicant's institution:

Jiangsu University Affiliated Hospital

研究负责人所在单位:

江苏大学附属医院

Affiliation of the Leader:

Jiangsu University Affiliated Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY2023H0907-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

江苏大学附属医院生物医学研究伦理委员会

Name of the ethic committee:

Ethics Committee on Biomedical Research of Affiliated Hospital of Jiangsu University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-09-13 00:00:00

伦理委员会联系人:

陈吉祥

Contact Name of the ethic committee:

Chen Jixiang

伦理委员会联系地址:

江苏省镇江市京口区解放路438号

Contact Address of the ethic committee:

438 Jiefang Road, Jingkou District, Zhenjiang City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 511 8502 6079

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

江苏大学附属医院

Primary sponsor:

Jiangsu University Affiliated Hospital

研究实施负责(组长)单位地址:

江苏省镇江市京口区解放路438号

Primary sponsor's address:

Jiangsu University Affiliated Hospital

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

镇江

Country:

China

Province:

Jiangsu

City:

Zhenjiang

单位(医院):

江苏大学附属医院

具体地址:

江苏省镇江市京口区解放路438号

Institution
hospital:

Jiangsu University Affiliated Hospital

Address:

Jiangsu University Affiliated Hospital

经费或物资来源:

中国红十字基金会

Source(s) of funding:

Chinese red cross foundation

研究疾病:

老年患者髋骨折  

Target disease:

Hip fractures in elderly patients

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究来探讨布比卡因脂质体对多模式镇痛的价值以评估 超声引导下布比卡因脂质体行髂筋膜阻滞对改善老年髋关节手术患者术后疼痛和减少镇痛药消耗的有效性和安全性,并探讨术前应用布比卡因脂质体行神经阻滞对老年髋关节手术患者术后认知功能的影响。  

Objectives of Study:

This study aims to explore the value of bupivacaine liposomes for multimodal analgesia, to evaluate the effectiveness and safety of ultrasound-guided liposomal bupivacaine for iliac fascia block in improving postoperative pain and reducing analgesic consumption in elderly patients undergoing hip surgery, and to investigate the impact of preoperative use of bupivacaine liposomes for nerve block on postoperative cognitive function in elderly patients undergoing hip surgery

药物成份或治疗方案详述:

布比卡因脂质体是把布比卡因封存在了载体分子中以延长其在作用部位停留时间的一种布比卡因新剂型,是常见的术后镇痛药物属于阿片类药物。已经被FDA批准用单次剂量局部浸润的方式来缓解患者囊炎切除术和痔切除术的术后疼痛。 脂质体有许多的优点。其与细胞膜的亲和力强,可以增加被包裹药物穿透细胞的能力。靶向性好,可以让药物在脾、肝、肾、骨髓、淋巴炎症以及肿瘤等部分分布大大增加。对药物的缓释作用可以提高药物在局部的浓度,降低血药浓度,从而延长其作用的时间并降低毒性。 布比卡因脂质体是一种将布比卡因封存在载体分子中,以延长其在作用部位停留时间的新剂型布比卡因。目前,布比卡因脂质体主要是使用DepoFoam技术制作成的,每一个微粒都是由众多封存了布比卡因的水性腔室和隔开腔室的脂质分子层构成的。 布比卡因作为一种酰胺类局部麻醉药,通过激活电压依赖的钠通道起到相应的作用,没有电荷的布比卡因跨过神经细胞膜,一旦带电荷,就会与其内部的钠通道衔接,并将其激活。 

Description for medicine or protocol of treatment in detail:

Upivacaine liposomes are a new form of bupivacaine that encapsulates bupivacaine in carrier molecules to extend its residence time at the site of action. They are a common postoperative analgesic drug belonging to the opioid class. It has been approved by the FDA to use a single dose of local infiltration to alleviate postoperative pain in patients undergoing cystectomy and hemorrhoidectomy. Liposomes have many advantages. Its strong affinity with cell membranes can increase the ability of encapsulated drugs to penetrate cells. Good targeting can greatly increase the distribution of drugs in the spleen, liver, kidney, bone marrow, lymphoinflammation, and tumors. The sustained release effect of drugs can increase their local concentration, reduce blood drug concentration, thereby prolonging their duration of action and reducing toxicity. Bupivacaine liposomes are a new dosage form of bupivacaine that encapsulates bupivacaine in carrier molecules to extend its residence time at the site of action. At present, bupivacaine liposomes are mainly made using DepoFoam technology, and each particle is composed of numerous aqueous compartments containing bupivacaine and lipid molecular layers separating the compartments. Bupivacaine, as an amide based local anesthetic, plays a corresponding role by activating voltage dependent sodium channels. Uncharged bupivacaine crosses the nerve cell membrane, and once charged, it connects with its internal sodium channels and activates them. 

纳入标准:

Inclusion criteria

排除标准:

①术前访视发现已有明显认知功能受损MMSE评分(见附表2)文盲<17分,小学<20分,初中及以上<24分); ②髋部手术史; ③阿片类药物或酒精滥用史; ④慢性疼痛病史; ⑤神经系统疾病; ⑥严重视力障碍; ⑦贫血(Hb<80g/L),凝血障碍; ⑧无法与医生进行有效的口头沟通; ⑨中途自愿退出研究; ⑩术前合并心衰、呼吸功能严重降低、严重心律失常,控制不良的高血压病、糖尿病等基础疾病患者。

Exclusion criteria:

① Preoperative visits revealed significant cognitive impairment with MMSE scores (see Appendix 2). Illiteracy<17 points, primary school<20 points, and middle school and above<24 points; ② History of hip surgery; ③ History of opioid or alcohol abuse; ④ History of chronic pain; ⑤ Neurological disorders; ⑥ Severe visual impairment; ⑦ Anemia (Hb < 80g/L), coagulation disorders; ⑧ Unable to communicate effectively with doctors verbally; ⑨ Voluntary withdrawal from the study midway; ⑩ Preoperative patients with basic diseases such as heart failure, seriously decreased respiratory function, severe arrhythmia, and poorly controlled hypertension and diabetes.

研究实施时间:

Study execute time:

From 2024-04-01 00:00:00 To 2026-04-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-04-01 00:00:00 To 2026-04-01 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

40

Group:

Experimental group

Sample size:

干预措施:

单次布比卡因脂质体266mg髂筋膜阻滞

干预措施代码:

Intervention:

Single dose bupivacaine liposome 266mg iliac fascia block

Intervention code:

组别:

对照组

样本量:

40

Group:

Control group

Sample size:

干预措施:

单次0.375%罗哌卡因20-30ml髂筋膜阻滞

干预措施代码:

Intervention:

Single dose 0.375% ropivacaine 20-30ml iliac fascia block

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏大学附属医院 

单位级别:

三甲 

Institution
hospital:

Jiangsu University Affiliated Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

谵妄

指标类型:

次要指标

Outcome:

delirium

Type:

Secondary indicator

测量时间点:

术前1天,术后1-7天

测量方法:

CAM量表

Measure time point of outcome:

1 day before surgery, 1-7 days after surgery

Measure method:

CAM scale

指标中文名:

疼痛

指标类型:

主要指标

Outcome:

Pain

Type:

Primary indicator

测量时间点:

髂筋膜阻滞前30min,阻滞后30min;术后6h、12h、24h、48h

测量方法:

VAS量表

Measure time point of outcome:

30 minutes before iliac fascia block, 30 minutes after block; 6 hours, 12 hours, 24 hours, and 48 hours after surgery

Measure method:

VASscale

指标中文名:

睡眠质量

指标类型:

次要指标

Outcome:

sleep quality

Type:

Secondary indicator

测量时间点:

术前1天,术后1-3天

测量方法:

阿森斯失眠量表

Measure time point of outcome:

1 day before surgery, 1-3 days after surgery

Measure method:

athens insomnia scale

指标中文名:

PCIA按压次数

指标类型:

主要指标

Outcome:

PCIA Press Times

Type:

Primary indicator

测量时间点:

术后48h内

测量方法:

Measure time point of outcome:

Within 48 hours after surgery

Measure method:

指标中文名:

补救镇痛次数

指标类型:

主要指标

Outcome:

Remedial analgesia frequency

Type:

Primary indicator

测量时间点:

术后72h内

测量方法:

Measure time point of outcome:

Within 72 hours after surgery

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age 99 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

电脑随机分配

Randomization Procedure (please state who generates the random number sequence and by what method):

Computer random allocation.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

药物准备是由不参与试验研究的麻醉医生准备的,并对患者进行神经阻滞。主麻医生、术者、患者本人均不知道接受何种干预。

Blinding:

Drug preparation is prepared by anesthesiologists who do not participate in the experimental study and perform nerve block on patients. The chief anesthesiologist, surgeon, and patient themselves do not know what kind of intervention to receive.

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

如有需要可向通讯作者索取

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

If necessary, you can request it from the corresponding author

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

一为电子病历系统、二为数据采集信息表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

One is the electronic medical record system, and the other is the data collection information table

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2024-03-12 09:56:55